Add to Calendar 5/19/2021 8:00:00 AM 5/19/2021 4:00:00 PM State of Possible Conference 2021
The State of Possible Conference celebrates how the life sciences make the impossible possible. As MassBio’s annual meeting, the State of Possible Conference taps today’s brightest minds for engaging conversations on the latest developments in our industry, key insights from the past year, and building a better future for patients around the world.
Join MassBio and more than 800 virtual attendees for a free, interactive day of networking, keynotes, panel discussions, and Possible Talks from some of the most inspiring voices in the industry.

Webinar, click "live-stream" button to view
Senior Vice President and Head of Global Development Operations, Bristol Myers Squibb
Kathryn (Kate) Owen is Senior Vice President and Head of Global Development Operations (GDO) within Bristol Myers Squibb. In this role, Kate leads and manages all operations related to the conduct of clinical trials across the portfolio - clinical pharmacology studies as well as Phase I through IV. She is also responsible for the data management and data standards, including the tools, systems and processes to support efficient clinical trial execution. The remit of the position includes the oversight of the business systems in support of health economics outcome research (HEOR), investigator sponsored research (ISR), named patient programs (NPP), and data sharing in relation to marketed products. In addition, Kate is responsible for ensuring business, GCP compliance and is building greater capability in biospecimen and bioimaging management in relation to clinical trial execution. While Kate’s responsibilities focus on global operational execution, she has a passion for ensuring the opportunity and the education of clinical trials is afforded broadly. Kate joined Bristol Myers Squibb in July 2017 from Novo Nordisk, where she served as Vice President of Clinical Trial Management (CTM) and global sponsor of RBM design & implementation. Prior to this, she spent more than eight years in a range of positions of increasing responsibility at Covance after having started her career in the UK in oncology focused biotech. Kate received her undergraduate degree from Royal Holloway, University of London in Biology.

Brought to you by